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Abstract
Streptococcus pneumoniae is the world’s leading cause of pneumonia, bacteremia, meningitis and otitis media. A major
pneumococcal virulence factor is the cholesterol-dependent cytolysin, which has the defining property of forming pores in
cholesterol-containing membranes. In recent times a clinically significant and internationally successful serotype 1 ST306
clone has been found to express a non-cytolytic variant of Ply (Ply306). However, while the pneumococcus is a naturally
transformable organism, strains of the ST306 clonal group have to date been virtually impossible to transform, severely
restricting efforts to understand the role of non-cytolytic Ply in the success of this clone. In this study isogenic Ply mutants
were constructed in the D39 background and for the first time in the ST306 background (A0229467) to enable direct
comparisons between Ply variants for their impact on the immune response in a macrophage-like cell line. Strains that
expressed cytolytic Ply were found to induce a significant increase in IL-1b release from macrophage-like cells compared to
the non-cytolytic and Ply-deficient strains in a background-independent manner, confirming the requirement for pore
formation in the Ply-dependent activation of the NLRP3 inflammasome. However, cytolytic activity in the D39 background
was found to induce increased expression of the genes encoding GM-CSF (CSF2), p19 subunit of IL-23 (IL23A) and IFNb
(IFNB1) compared to non-cytolytic and Ply-deficient D39 mutants, but had no effect in the A0229467 background. The
impact of Ply on the immune response to the pneumococcus is highly dependent on the strain background, thus
emphasising the importance of the interaction between specific virulence factors and other components of the genetic
background of this organism.
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Introduction
Streptococcus pneumoniae (the pneumococcus) is responsible for
almost 1 million deaths in children under 5 years of age annually,
and is the leading cause of diseases such as pneumonia,
bacteremia, meningitis and otitis media. A key virulence factor
of the pneumococcus is the pore-forming toxin pneumolysin (Ply),
which is a member of the family of cholesterol-dependent
cytolysins and a potential target in future vaccine formulations
[1–6]. Mutants lacking Ply have been shown to be attenuated in
murine models of infection [7]. More specifically, Ply-deficient
mutants have been characterised by reduced induction of
pulmonary inflammation due to delayed cell recruitment into
the lungs, particularly affecting neutrophil responses and the
distribution of B and T lymphocytes in and around inflamed
bronchioles [8,9]. The defining property of Ply is its ability to form
pores in cholesterol-containing membranes, causing potent induc-
tion of inflammation and tissue damage [7,9–13]. However, Ply
has a number of other properties including antibody-independent
activation of the classical complement pathway and binding to toll-
like receptor 4 (TLR4) [14–16]. Amongst a number of responses,
pore formation activates the NLRP3 inflammasome, leading to
Caspase-1 activation and subsequent processing and release of IL-
1b from immune cells [17]. There is some evidence to suggest that
Ply-induced pore formation is responsible for potassium efflux and
lysosomal destabilization that are detected either directly by
NLRP3 or via intermediary factors leading to inflammasome
assembly and Caspase-1 activation [17]. Therefore, IL-1b release
is indicative of Ply-dependent activation of the NLRP3 inflamma-
some [17].
Serotype 1 strains of S. pneumoniae are a significant cause of
disease worldwide and are frequently responsible for outbreaks of
IPD in otherwise healthy individuals [18–23]. In the last 20 years
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the ST306 serotype 1 clone has seen a dramatic expansion across
the globe responsible for more than 80% of cases of serotype 1
disease in many jurisdictions [24–28]. Interestingly the ST306
clone expresses a non-cytolytic Ply variant that retains the ability
to bind to cholesterol-containing membranes and oligomerise, but
cannot form pores [25].
Previous work has also found that a hypervirulent serotype 1
strain 4496 of the clonal cluster 615 produced a Ply variant
(Ply4496) with very low specific hemolytic activity, 1.6% of PlyD39
[29,30]. However, when D39 was constructed to express Ply4496
the resultant mutant was similarly virulent to wild-type D39 in
mice in terms of survival and was significantly more virulent than
Ply-deficient D39 [29]. In addition, D39 constructed to express an
engineered Ply toxoid PdT (D385N/C428G/W433F) that retains
only 0.001% of PlyD39 hemolytic activity, was similar in virulence
to D39 in terms of survival, but was significantly more virulent
than the Ply-deficient strains [7]. The apparent importance of Ply
to pathogenesis even in the absence of hemolytic activity highlights
the lack of understanding of the relative importance of cytolytic
activity to pneumococcal pathogenesis as a whole.
However, efforts to characterise the significance of this
phenomenon have been frustrated by the genetically intractable
nature of a number of serotype 1 strains such as those of the
ST306 clonal group. While attempts to characterise low and non-
cytolytic variants, such as Ply4496 and Ply306, respectively, have
been performed [25,29,31], these studies have either relied on
comparisons between different wild-type strains that express
different Ply variants in the context of numerous other known
and unknown strain-specific differences, or performed compari-
sons between isogenic strains, but in the context of an alternative
strain background that is easily transformable. In both cases the
significance of the interaction between the cytolytic activity of Ply
and the clinically relevant strain background is not considered,
representing a significant shortcoming in understanding the role of
Ply in clinically important and internationally successful strains.
The current studies are the first to detail mutations made in a
strain of the ST306 clonal group and the first to detail
comparisons between the immune response to isogenic Ply
mutants in either the D39 or ST306 (strain A0229467)
backgrounds. Ply-deficient mutants (D39DPly & A0229467DPly)
and mutants expressing engineered non-cytolytic derivatives that
cannot bind to mammalian cell membranes, oligomerise or form
pores (L460D [32]) were constructed in the D39 and A0229467
backgrounds. In this work the cytolytic activity of Ply was
confirmed to be responsible for activation of the NLRP3
inflammasome in a strain-independent manner. However, more
broadly the immune response of a macrophage-like cell line
[33,34] to different Ply variants was found to be highly dependent
on the strain background and appeared to suggest that the
naturally non-cytolytic strain had adapted to the lack of cytolytic
Ply. In addition, this work highlights the significant interaction
between specific virulence factors and other strain-specific
components of the organism’s genetic composition.
Materials and Methods
Ethics statement
This study was conducted in compliance with the Australian
Code of Practice for the Care and Use of Animals for Scientific
Purposes (7th Edition 2004) and the South Australian Animal
Welfare Act 1985. All animal experiments were approved by the
Animal Ethics Committee of the University of Adelaide. Ethics
approval was obtained for molecular analyses of the A0229467
strain from the Central Australian Human Ethics Committee of
the Northern Territory Department of Health.
Strains and media
The virulent serotype 2 strain, D39 (NCTC 7466) was used in
this study [35]. The serotype 1 blood isolate belonging to the
ST306 clonal group (A0229467) was obtained from the Alice
Springs Hospital. Serotyping and multi locus sequence typing were
performed by the Public Health Microbiology Laboratory at
Queensland Health Scientific Services. Opaque-phase variants of
all strains were selected on Todd-Hewitt broth supplemented with
1% yeast extract (THY)-catalase plates [36], and these were used
in all animal experiments. Before infection, the bacteria were
grown in serum broth (SB) (nutrient broth [10 g/l peptone
(Oxoid), 10 g/l Lab Lemco powder (Oxoid) and 5 g/l NaCl] and
10% [v/v] donor horse serum) to 16108 CFU/ml, and then
diluted to the relevant challenge dose. For all other experiments,
strains were grown at 37uC in a CO2-enriched atmosphere in a
casein-based semisynthetic liquid medium (C+Y) [37] to
16108 CFU/ml. Bacteria were pelleted, washed and resuspended
in PBS to 16108 CFU/ml.
PCR
PCR reactions were performed using a Mastercycler Nexus
thermal cycler (Eppendorf). Reactions were performed using the
Phusion-Flash PCR system (Thermo Scientific). Overlap-extension
PCR was carried out as previously described [38,39].
Transformation of pneumococci
For S. pneumoniae D39, preparation of competent cells and
subsequent transformation was performed using the complete
transformation medium (CTM) method [40,41]. A0229467 was
transformed by diluting an overnight culture in C+Y medium in a
1:1 mixture of C+Y medium and Dulbecco’s Modified Eagle’s
Medium (DMEM; Gibco, Grand Island, N.Y.) supplemented with
10% heat-inactivated fetal calf serum (FCS). After 2 h at 37uC,
50 ng/ml competence stimulating peptide 1 (CSP-1) was added,
followed 15 min later by donor DNA (approximately 1 mg). After a
further 2 h incubation at 37uC, transformation mixes were plated
on blood agar supplemented with the appropriate antibiotics.
Construction of Pneumolysin mutants
D39DPly was constructed by replacing the ply open reading
frame with the gene encoding chloramphenicol acetyltransferase
(cmlR) and subsequent selection of chloramphenicol resistant
recombinants. D39::Ply306 was constructed by replacing cml
R in
D39DPly with ply306, which was amplified from A0229467.
D39::Ply306 recombinants were selected for the loss of chloram-
phenicol resistance as previously described [42]. D39::PlyL460D
was constructed by replacing cmlR in D39DPly with the plyL460D
allele, which was generated by site-directed mutagenesis and
overlap-extension PCR using primers RHPlyF(5) (GGT GGT
GCT TAT GCT TTG TCG), RHPlyR(5) (GTG GGC AAT GAC
AAA GGA TGT G), RHPlyL460DF (CCT GAG GAT AAT
CAG TTG TTC C) and RHPlyL460DR (GGA ACA ACT GAT
TAT CCT CAG G). D39::PlyL460D recombinants were selected
for loss of chloramphenicol resistance, as described above for
D39::Ply306.
Ply mutants in the A0229467 background were constructed by
replacing the ply ORF of a ST306 derivative with a rpsL mutation
with the Janus cassette [43] (designated A0229467rpsLply::Janus).
Insertion of the Janus cassette suppresses the rpsL StrepR
phenotype and confers kanamycin resistance. This construct was
Ply Variant-Dependent Immune Response
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then transformed with genomic DNA from D39DPly and transfor-
mants were counter-selected by plating on BA+Strep. Genomic DNA
was then extracted from a confirmed StrepR/KanS transformant that
produced no Ply protein, as judged by western blotting and used to
transformA0229467rpsLply::Janus. Deletion of the ply gene from one
of the resultant second generation StrepR/KanS transformants
(designated A0229467DPly) was confirmed by western blotting and
DNA sequencing. This two-step procedure essentially eliminates co-
transformation of other genetic markers from the donor DNA into
the A0229467 background. An analogous procedure was used to
replace the Janus cassette in A0229467rpsLply::Janus with the
ply alleles from wild type D39 and D39::PlyL460D, generating
A0229467::PlyD39 and A0229467::PlyL460D, respectively.
Quantitative Western Blotting
Relative expression of Ply was determined by quantitative
western blotting on whole cell lysates using the Odyssey Infrared
Imaging System and associated software package (LI-COR
Biosciences), as previously described [29].
Hemolysis Assay
The hemolytic activity of pneumococcal lysates was determined
as described previously [5], using PBS-washed human erythro-
cytes. Approximately 50 mg of total lysate supernatant protein was
used for each sample in triplicate. The hemolytic activity was
defined as the dilution factor at which 50% hemolysis was
detected.
Animal studies
Outbred 5- to 6-week old female CD1 (Swiss) mice were used in
all challenge experiments. Mice were challenged intraperitoneally
with 100 ml of bacterial suspension containing approximately
16104 CFU in SB. The challenge dose was confirmed retrospec-
tively by serial dilution and plating of the inocula on blood agar.
For survival experiments, mice were closely monitored for signs of
illness over 14 days and were humanely euthanised when terminal
infection was reached. Heart blood was taken from euthanised
mice and plated on blood agar to confirm the presence of S.
pneumoniae.
Cell Culture and differentiation of THP-1 cells into a
macrophage-like cell type
All tissue culture media and reagents were obtained from Gibco.
THP-1 cells (ATCC TIB-202) were grown in 95% air-5% CO2 at
37uC in complete RPMI medium (RPMI with phenol red,
supplemented with 10% FCS, 10 mM HEPES, 50 IU/ml
penicillin and 50 mg/ml streptomycin). 10 cm dishes were seeded
with 3.56106 THP-1 cells and differentiated by adding phorbol
12-myristate 13-acetate (PMA) to a final concentration of 10 ng/
ml and incubating for three days at 37uC in 95% air-5% CO2.
Differentiated cells attach to the plastic surface. Following the
three day incubation cells were washed twice with complete RPMI
and then rested at 37uC in 95% air-5% CO2 in complete RPMI
for a further 3 days.
Co-incubation of differentiated THP-1 cells with
S. pneumoniae
Differentiated THP-1 cells were washed twice with PBS before
adding 5 ml of RPMI without antibiotics, FCS, HEPES or phenol
red. Bacteria (100 ml) were added to each dish at a 10:1
(bacteria:THP1 cells) ratio (100 ml PBS was added to each resting
control) and incubated at 37uC in 95% air-5% CO2 for 6 h before
RNA extraction, or 16 h if collecting supernatants for enzyme-
linked immunosorbent assay (ELISA).
ELISAs
Following 16 h co-incubation, the culture medium was collected
and centrifuged at 16,0006g to pellet the bacteria. IL-1b in the
resultant supernatants was quantified using the BD OptEIA
Human IL-1b ELISA Kit II (BD Biosciences) and scanned on a
SPECTROstar Omega microplate reader (BMG Labtech),
according to the manufacturer’s instructions.
PCR Arrays
Following 6 h co-incubation, RNA was extracted from infected
THP-1 cells using the PureLink RNA Mini Kit (Life Technolo-
gies), including on-column DNase digestion, according to the
manufacture’s instructions. Purified RNA was analysed on a
LightCycler 480 II (Roche) by qRT-PCR using the RT2 Profiler
PCR Array Human Innate and Adaptive Immune Responses kit
(Qiagen), according to the manufacturer’s instructions. Data were
generated from quadruplicate samples.
Statistical Analyses
The one-way ANOVA with the Tukey’s multiple comparisons
test was used to compare the mean survival times of mice, the
mean relative Ply expression by quantitative Western Blot and the
mean relative amount of IL-1b release by ELISA. The One-way
ANOVA and Krustal-Wallis multiple comparisons test were
performed using GraphPad Prism 6 for Mac. Statistical analyses
for PCR Array data were performed according to the manufac-
turer’s instructions. Changes in expression .2 fold and P,0.05
were considered statistically significant.
Results
Loss of the Ply cytolytic property increases mouse
survival
D39 was constructed to express the naturally occurring non-
cytolytic Ply306 variant. The virulence of D39, D39DPly and
D39::Ply306 was compared to determine whether the lack of
cytolytic activity exhibited by Ply306 would lead to increased
survival when expressed in D39. The survival times of groups of 12
mice challenged intraperitoneally with 104 CFU of each strain
D39, D39DPly or D39::Ply306 were compared (Fig. 1). The
median survival time of mice challenged with D39DPly was
significantly longer than both the wild type (P,0.001) and
D39::Ply306 (P,0.05), but there was a much smaller but
nevertheless statistically significant difference in median survival
times between the wild type and D39::Ply306 (P.0.05). Thus, we
confirm that while the cytolytic properties of Ply do contribute the
virulence of wild type D39, the non-cytolytic properties appear to
be much more important in this model.
Induction of IL-1b release is dependent on the cytolytic
activity of Ply but independent of the strain background
Table 1 lists the isogenic Ply mutants that were used in this
study and include mutants in both the D39 and A0229467
backgrounds. All 8 strains were cultured in C+Y broth, and
aliquots were taken for western blot and hemolytic activity
analyses. Quantitative western blotting of equal quantities of total
lysate supernatant protein confirmed that there were no significant
differences in the amounts of Ply protein produced by D39,
D39::Ply306, D39::PlyL460D, A0229467, A0229467::PlyD39 and
A0229467::PlyL460D (Fig. 2B). Ply was not detected in either the
Ply Variant-Dependent Immune Response
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D39DPly or A0229467DPly samples (Fig. 2A). Hemolysis assays
were used to determine the specific hemolytic activity of equal
quantities of total lysate supernatant protein of each strain. D39 and
A0229467::PlyD39 exhibited hemolytic activity at approximately
36103 and 26103 HU/mg lysate supernatant protein, respectively
(Table 1). Hemolytic activity was below the limit of detection (20
HU/mg lysate supernatant protein) for the remaining six strains,
which confirms that the Ply306-expressing strains and PlyL460D-
expressing strains are essentially non-hemolytic, as previously
described [25,32]. To confirm that lytic Ply (PlyD39) induces IL-
1b release when expressed in either the D39 or A0229467
background, differentiated THP-1 cells were co-incubated for
16 h separately with all eight strains listed in Table 2. Approxi-
mately 15.3 and 12.7 fold more released IL-1b was detected in the
presence of wild-type D39 and A0229467::PlyD39 compared to the
resting control, respectively (Fig. 3). In contrast, there was no
difference in the amount of IL-1b detected between the remaining
six samples and the resting control. Therefore, Ply-dependent IL-1b
release is associated with cytolytic activity of the toxin in a strain-
independent manner, and confirms for the first time using isogenic
strains that Ply-dependent activation of the NLRP3 inflammasome
requires cytolytic activity in a strain-independent fashion.
Differential expression of immune genes in differentiated
THP-1 cells is related to both the strain background and
Ply variant
The ability to genetically manipulate a strain of the ST306 clone
provided the opportunity to compare the immune response to
isogenic Ply clones in that background and D39, and distinguish
the contribution made by cytolytic activity to the immune response
from that of the ability to bind to the eukaryotic cell surface. The
immune response was characterised broadly and at the level of
transcription between isogenic Ply mutants in the D39 and
A0229467 backgrounds. The expression of 84 genes representing
key pathways in the response against bacteria were analysed in
vitro in PMA-activated THP-1 cells. Following PMA-driven
differentiation into a macrophage-like cell type, these cells were
incubated separately with each of the strains listed in Table 1 at a
1:10 ratio. An additional unchallenged ‘resting’ control was
included for each experiment. Significant changes in gene
expression were deemed to be those with changes $2 fold and
P,0.05. The impact of each strain on the viability of THP-1 cells
following 6 h co-incubation was determined by trypan blue
staining and no differences were found between any strain (data
not shown).
For the comparisons in the D39 background, the genes
encoding the p19 subunit of interleukin 23a (IL23A) and
granulocyte macrophage colony-stimulating factor (GM-CSF
[CSF2]) exhibited reduced expression in the presence of D39DPly,
D39::Ply306 and D39::PlyL460D compared to wild-type D39,
which suggests a link between the expression of these genes and
cytolytic activity (Table 2). Interestingly, despite significantly
reduced CSF2 expression compared to the wild type, D39DPly
was associated with significantly increased CSF2 expression
compared to D39::PlyL460D. In addition, both wild-type D39
and D39DPly were also associated with 16.17- and 2.33-fold (P,
0.01) increased CSF2 expression, respectively, compared to the
resting group, whereas neither D39::Ply306 nor D39::PlyL460D,
were associated with a change in CSF2 expression. In contrast,
IL23A expression was elevated 32.97 (D39), 10.23 (D39DPly) 8.12
(D39::Ply306) and 7.39 (D39::PlyL460D) fold (P,0.001) in the
presence of each of the four strains compared to the resting group.
Expression of the gene encoding interferon b1 (IFNB1) was
reduced compared to the wild type in the presence of D39DPly
and D39::Ply306, but not D39::PlyL460D (Table 2). A small but
significant reduction in the expression of the interleukin 8 (IL8)
was detected in the presence of both D39::Ply306 and
D39::PlyL460D compared to the wild type. However, IL8
expression was dramatically increased by 2206.18 (D39),
1133.71 (D39DPly), 1068.1 (D39::Ply306) and 915.76
(D39::PlyL460D) fold (P,0.01) in the presence of all four strains
compared to the resting control, indicating that IL8 expression is
dramatically induced by the pneumococcus in a largely Ply-
independent manner. Small but significant changes in expression
were observed for chemokine (C-X-C motif) ligand 10 (CXCL10)
and interferon regulatory factor 7 (IRF7) in the presence of
D39::Ply306 compared to the wild type (Table 2). In addition, the
expression of interleukin 10 (IL10) and interleukin 1a (IL1A)
genes was reduced in the presence of D39::PlyL460D compared to
the wild type (Table 2).
In comparison to the differences observed between D39 strains
expressing different Ply variants, very few changes in expression
were detected between the A0229467 strains. A 2.10-fold (P,
0.05) reduction in IFNB1 expression was detected in the presence
of A0229467DPly compared to the wild type. In contrast,
A0229467::PlyD39 induced a 7.62-fold (P,0.05) increase in
IFNB1 expression compared to A0229467DPly. The expression
of the gene encoding the CD8a molecule (CD8A) was reduced by
2.48-fold (P,0.05) in the presence of A0229467::PlyL460D
compared to A0229467DPly and the expression of the CSF2
gene was reduced by 2.33-fold (P,0.01) in the presence of
A0229467::PlyD39 compared to A0229467::PlyL460D. CSF2 ex-
Figure 1. Survival of mice challenged with isogenic Ply mutants
in D39. Survival times of groups of 12 CD1 mice challenged with
104 CFU of the indicated strain via the intraperitoneal route of
challenge. Statistical significance was calculated using the one-way
ANOVA and Kruskal-Wallis and Dunn’s multiple comparisons test (‘*’ P,
0.05; ‘**’ P,0.01, ‘***’ P,0.001).
doi:10.1371/journal.pone.0103625.g001
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pression was increased by 5.99, 10.5 and 4.51 fold (P,0.05) in the
presence of A0229467DPly, A0229467::PlyD39 and
A0229467::PlyL460D relative to the resting group, respectively.
Ply-independent changes in gene expression
Table 3 lists the genes that exhibited changed expression
between the resting groups and the challenge groups in a Ply-
independent manner. In particular, the genes encoding comple-
ment component 3 (C3), the CD86 molecule (CD86), myeloper-
oxidase (MPO) and nucleotide-binding oligomerisation domain-
containing protein 2 (NOD2) were significantly changed in the
presence of D39, but not A0229467 (Table 3). In contrast to D39,
9 genes exhibited reduced expression in the presence of A0229467
compared to the resting group but were unaltered in the presence
of D39 (Table 3). These included the genes encoding chemokine
receptor 5 (CCR5), the CD4 molecule (CD4), CD40 ligand
(CD40LG), CD11b (ITGAM), lymphocyte antigen 96 (LY96),
nucleotide-oligomerisation domain containing protein 1 (NOD1)
and toll-like receptor 1 (TLR1). Ply-independent changes in
expression that were similar between the two strain backgrounds
are listed in the supplementary section (File S1).
Discussion
While the importance of Ply as a pneumococcal virulence factor
has been known for decades, it is becoming increasingly clear that
the role Ply plays in disease is more complex than originally
thought. The apparent success of clonal types that express non-
cytolytic variants of Ply suggest that cytolytic activity may not be
an essential property in certain contexts. Furthermore, Ply variants
with low (Ply4496 [29]) and absent (Ply306 [this study]) cytolytic
activity suffer only small reductions in virulence compared to the
fully cytolytic wild-type D39 [29]. Given that the Ply306-expressing
D39 strain was shown to be significantly more virulent than Ply-
deficient D39, it is possible to conclude that the non-cytolytic
properties of Ply are essential for full virulence within the host. In
previous work it has been suggested that strains expressing non-
cytolytic Ply may have an advantage over cytolytic strains as they
do not activate the NLRP3 inflammasome and may be less
vulnerable to clearance from the host [17,31]. One such study,
which compared the ability of the cytolytic and non-cytolytic
clinical isolates to trigger IL-1b release, suggested a role for the
cytolytic activity of Ply in NLRP3 inflammasome activation [31].
However, given that the study was performed between different
isolates it is difficult to resolve the contribution to NLRP3
inflammasome activation made by Ply from that of other strain-
specific differences in genetic background. In contrast, the use of
Figure 2. Ply expression. Ply expression analysis. Ply expression was compared between D39, D39DPly, D39::Ply306, D39::PlyL460D, A0229467,
A0229467DPly, A0229467::PlyD39 and A0229467::PlyL460D by quantitative western blot using Ply-specific mouse antisera (A) The size of Ply (53 kDa)
is indicated. The mean fluorescence units relative to D39 from biological triplicates are shown (B). Error bars indicate the SEM. Relative expression was
compared between strains using the one-way ANOVA and Kruskal-Wallis and Dunn’s multiple comparisons test, where P,0.05 would indicate
statistical significance.
doi:10.1371/journal.pone.0103625.g002
Ply Variant-Dependent Immune Response
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isogenic Ply mutants in the present study was able to confirm that
only bacteria expressing the cytolytic Ply variant, PlyD39, were
capable of triggering IL-1b release from cultured human
macrophage-like cells, irrespective of the strain background.
Construction of isogenic Ply mutants in the D39 and A0229467
backgrounds provided an opportunity to broadly characterise the
differences in the induced immune response associated with the
different Ply variants in two backgrounds. This study examined the
effects of strain background and Ply variant at the transcriptional
level, which is one of the earliest measureable parameters of the
cellular response to pathogens. It focuses on a select subset of genes
known to be involved in the host immune response against
bacteria [44]. Firstly the ability of Ply to bind to the cell surface
was not associated with any consistent changes in gene expression
in either background, as the Ply306 v PlyL460D and PlyD39 v
PlyL460D comparisons showed. In the D39 background, the
Figure 3. Ply-dependent induction of IL-1b release requires cytolytic activity. Differentiated THP-1 cells were co-incubated with bacteria at
a 1:10 ratio for 16 h. Supernatants were collected and IL-1b levels measured by ELISA. The mean quantity of IL-1b detected from resting samples is set
at a relative value of 1 (dashed line), with all data points plotted as fold-change from this value. Error bars indicate the mean with standard deviation.
Significant increases in IL-1b levels are highlighted, *** = P,0.001, n = 4.
doi:10.1371/journal.pone.0103625.g003
Table 1. Hemolytic activity of the strains used in this study.
Strain Specific Hemolytic Activity (HU/mg)a Mutant Source (Ref)
D39 36103 -c
D39DPly -b [29]
D39::Ply306 - This study
D39::PlyL460D - This study
A0229467 - -c
A0229467DPly - This study
A0229467::PlyD39 2610
3 This study
A0229467::PlyL460D - This study
aHemolytic units per mg of cell lysate supernatant protein.
bHemolytic activity below the limit of detection of 20 HU/mg.
cWild type strains.
doi:10.1371/journal.pone.0103625.t001
Ply Variant-Dependent Immune Response
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cytolytic activity of Ply induces increased expression of genes
encoding pro-inflammatory cytokines, such as GM-CSF and IL-
23a, as well as IFNb1. CSF2, which encodes GM-CSF, remained
either unchanged or was weakly up-regulated in the presence of
D39 strains expressing no or non-cytolytic Ply, but was signifi-
cantly induced upon expression of cytolytic Ply. GM-CSF
stimulation of macrophages in culture has been shown to induce
an activated/pro-inflammatory ‘‘M1’’ phenotype, leading to
increased production of other pro-inflammatory cytokines upon
exposure to bacterial components [45]. In vivo it is involved in
recruitment of granulocytes, including neutrophils, and macro-
phages to sites of inflammation, as well as promoting survival and
activation of these cell types within the tissue [45]. All D39 strains
induced a significant increase in IL23A expression. However, the
expression of cytolytic Ply in this background induced a much
greater increase in IL23A expression than the other variants,
which may at least in part be related to the induction of CSF2. IL-
23 also induces expression of pro-inflammatory cytokines such as
TNF and IL-6. It has been identified as an important factor in the
maintenance and function of Th17 cells [46,47], which have been
shown to be key players in the host response against the
pneumococcus [48,49]. IFNB1 expression was also only induced
by D39 expressing cytolytic Ply, possibly due to the detection of
bacterial nucleic acids in the cytoplasm of the THP-1 cells that
may have entered via the Ply pore [50]. CXCL10 was the only
gene that exhibited increased expression in the presence of any
one of the non-cytolytic variants versus the wild-type, which
occurred in the presence of D39::Ply306 and may point to
unknown properties of Ply.
Unlike D39, the A0229467 strains did not induce any consistent
changes in gene expression that were associated with cytolytic
activity. Interestingly, in contrast to the D39 strains, the overall
effect of A0229467 strains seemed to be a general down-regulation
of immune genes, independent of Ply expression. Whereas D39
induced up-regulation of a number of genes not induced by
A0229467 (including C3, MPO and NOD2), A0229467-specific
Ply-independent differential gene regulation was almost universal-
ly the down-regulation of genes, including CCR5, CD4, ITGAM,
NOD1 and TLR1. This might suggest a mechanism by which
A0229467 can compensate for a lack of cytolytic activity by
inducing a general suppression of the immune response in this cell
line. A notable exception was the increased CSF2 expression
Table 2. Ply-dependent changes in expression in the D39 background.
D39 v D39DPly D39 v Ply306 D39 v PlyL460D D39DPly v PlyL460D
Gene
CSF2 26.94** 29.15** 213.99** 22.01**
IFNB1 26.18** 25.35* ns ns
IL23A 23.22*** 24.06*** 24.46*** ns
CXCL10 ns 2.15* ns ns
IL8 ns 22.07** 22.41 ns
IRF7 ns 22.05* ns ns
IL10 ns ns 22.65** ns
IL1A ns ns 22.56* ns
Significant changes in expression are $2 fold and P,0.05. (‘*’P,0.05; ‘**’ P,0.01; ‘***’ P,0.001).
ns denotes changes in expression that are not significant.
doi:10.1371/journal.pone.0103625.t002
Table 3. Strain-dependent Ply-independent changes in expression relative to resting.
Gene D39 D39DPly D39::Ply306 D39::PlyL460D
C3 6.04* 4.01* ns 3.54*
CD86 22.51* 22.49* ns 22.28*
MPO 2.16* 2.10* 2.63* 2.44**
NOD2 2.33** 2.87** 2.30*** 2.51**
Gene A0229467 A0229467DPly A0229467::PlyD39 A0229467::PlyL460D
CCR5 23.43* 23.12* 23.05* 23.95*
CD4 22.13* ns 23.05* 23.08*
CD40LG 23.25** 23.23** 23.39** 22.97*
ITGAM 22.80** 22.42* 23.28** 22.43**
LY96 22.64** 22.61** 22.33** 22.08**
NOD1 23.00* 22.01* 22.66* 22.48*
TLR1 22.37*** 22.50*** 23.77*** 23.75***
Significant changes in expression are $2 fold and P,0.05. (‘*’P,0.05; ‘**’ P,0.01; ‘***’ P,0.001).
ns denotes changes in expression that are not significant.
doi:10.1371/journal.pone.0103625.t003
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consistently associated with the A0229467 background. Contrary
to the cytolytic Ply-dependent increase in expression seen in the
D39 background, A0229467 appears to cause an up-regulation of
CSF2, with only a slight increase in expression between cytolytic
and non-cytolytic Ply-expressing strains. The dramatic increase in
IL8 expression observed for all strains is consistent with detection
of bacterial cell components by pattern-recognition receptors and
secondary stimulation by proinflammatory cytokines as IL-1 and
TNF [51–54]. The implications of these Ply-independent changes
in gene expression merit further investigation.
In summary, the ability to genetically manipulate A0229467
made it possible to perform the first direct comparisons between
the immune response to isogenic Ply mutants in the naturally non-
cytolytic A0229467 background. This work confirmed that the
cytolytic activity of Ply is responsible for IL-1b release in a strain-
independent manner. Furthermore, this work showed that the
cytolytic activity of Ply was important for the immune response to
the naturally cytolytic D39, but had very little impact on the
response to the naturally non-cytolytic A0229467, suggesting that
A0229467 has adapted to the absence of Ply cytolytic activity.
Supporting Information
File S1 Ply-independent changes in expression that
were similar between the two strain backgrounds.
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